Instant HIV Tests Destined for UAE as Demand Increases for Immigration and Emergency Care HALIFAX, March 21 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in premium rapid diagnostic solutions, announced today that it has received an order for 10,000 MiraWell(R) Rapid HIV Tests (MiraWell(R) HIV) from its Middle East distributor, Spree Trading, a member of the Shawwa Group International, which is a multibillion-dollar global corporation with healthcare and diagnostic sales divisions. These tests are destined for the Dubai market in the United Arab Emirates (UAE), where they will be sold to immigration services, hospitals and other healthcare facilities providing rapid HIV testing. "We believe the UAE market and the Middle East region generally hold a great deal of potential for the sale of MedMira's products," said Stephen Sham, chairman and CEO, MedMira. "Spree Trading's aggressive marketing plans and healthcare experience are key to capitalizing on sales of our products in this growing market." In 2005, MedMira completed the registration process with the UAE Ministry of Health. Spree Trading will be pursuing further product evaluations, tender opportunities, and new sales channels for MedMira's full product line. MedMira will work closely with Spree Trading to evaluate and seek new market opportunities for other MedMira products including an over-the-counter (OTC) rapid HIV test and rapid test for HIV/Hepatitis C (HCV) co-infections. Sham continued, "The sophisticated healthcare system in the UAE will enable MedMira to expand our product offering in the region to include OTC tests and other, more advanced rapid diagnostic solutions." MiraWell(R) HIV is the fastest flow-through rapid HIV test in the world, providing results instantly. MedMira's rapid tests have a wide range of applications including occupational exposures, labor & delivery and general screening. When used for general screening purposes, rapid HIV tests can provide significant value, especially in a market such as Dubai where expatriates make up 80% of the population and must be tested for HIV every two years as part of the visa renewal process. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow- through rapid diagnostic tests. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV and hepatitis C. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively. MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used in clinical laboratories, hospitals, and clinics where professional counselling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter (OTC) in pharmacies throughout Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MiraCare(TM) is sold through MedMira's distributor network to pharmacies, hospitals and laboratories in the European Union. MedMira delivers rapid diagnostic solutions to healthcare communities around the globe. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Guilin, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail: ; Andrea Young, Corporate Communications, Tel. (902) 450-1588, Email:

Copyright